Weight and T2D: Case 1

CE / CME

Shifting the Treatment Paradigm of Weight Management and Type 2 Diabetes in Primary Care: Interactive Case Challenge 1

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: October 31, 2023

Expiration: October 30, 2024

Martin J. Abrahamson
Martin J. Abrahamson, MD, FACP
Debbie Hinnen
Debbie Hinnen, APN, BC-ADM, CDCES, FAAN

Activity

Progress
1
Course Completed

Presurvey

A patient newly diagnosed with type 2 diabetes (T2D) presents with an A1C of 8.5% with no other risk factors. The patient has an additional goal of weight loss (BMI 32 kg/m2). Which of the following is the best option for initial therapy?

A patient with T2D (A1C 8.5%) and obesity (class I, BMI 30 kg/m2) currently is receiving metformin monotherapy and is requesting an agent to assist with weight loss. Which of the following agents is considered to have both a very high efficacy for weight loss and a very high efficacy for glucose lowering?

Which of the following would be best for a patient with T2D (A1C 7.8%) and obesity (class II, BMI 36 kg/m2) who achieves a 5% weight loss after 3 months of taking tirzepatide, which currently is titrated to 7.5 mg once weekly?